Abstract:An increasing number of artemisinin (ARS) and its derivatives have been reported for their potential therapeutic value of human cancer. However, their therapeutic potencies are limited owing to their poor pharmacokinetic profiles. Our previous studies showed that a lead compound ARS4 originated from incorporating the pharmacophore of the approved chemotherapeutic agent melphalan into the basic skeleton of artemisinin with a succinic linker exhibited an excellent toxicity to human ovarian cancer cells and low cytotoxicity to normal cells. The mechanism studies demonstrated that it inhibited the growth and proliferation of ovarian cancer cells and resulted in S-phase arrest, apoptosis and inhibition of migration. Meanwhile, it exhibited excellent antitumor activities in animal models. Herein, further structure optimization for this lead compound ARS4 was performed and nineteen novel derivatives were designed and synthesized. Among them, compounds 10-12, 15, 16, 18 and 19 demonstrated powerful cytotoxic effects against human liver cancer and ovarian cancer cell lines, with their IC50s below 0.86 μM against Hep3B and A2780 cell lines, which are superior to that of ARS4. Four compounds (11, 15, 16 and 18) were selected to further evaluate their antitumor activities in in vitro and in vivo ovarian and liver cancer models, the results indicated that compound 18 exhibited the best therapeutic effect, not only effectively inhibited the growth of 7404 xenograft and Huh7 xenograft, but also presented a good dose-dependent inhibition toward the growth of A2780 xenograft. Overall, based on these positive results, these novel chemical structures may provide a new inspiration for the discovery of novel antitumor agents originated from artemisinin scaffolds.

Synthesis and biological evaluation of novel artemisone–piperazine–tetronamide hybrids

Synthesis of artemisinin-piperazine-furan ether hybrids and evaluation of in vitro cytotoxic activity

Synthesis and Antitumor Activity of 2-Aryl-1, 2, 4-Triazolo[1, 5-A] Pyridine Derivatives

Synthesis and antiproliferative evaluation of new hybrids of piperine and acylhydrazone

Synthesis and anticancer activity of novel C6-piperazine substituted purine steroid–nucleosides analogues

Design of novel artemisinin-like derivatives with cytotoxic and anti-angiogenic properties

Development and evaluation of novel artemisinin-isatin hybrids with potential anti-leukemic cytotoxicity

Synthesis of Novel Ring-Contracted Artemisinin Dimers with Potent Anticancer Activities.

Design, synthesis and biological evaluation of rhein–piperazine–furanone hybrids as potential anticancer agents

Structural optimization and biological evaluation for novel artemisinin derivatives against liver and ovarian cancers

Facile synthesis and biological evaluation of tryptamine-piperazine-2,5-dione conjugates as anticancer agents

Synthesis and cytotoxic evaluation of novel symmetrical taspine derivatives as anticancer agents.

Design, Synthesis and Antiproliferative Activities of Artemisinin Derivatives Containing A Substituted Piperazine

Synthesis, anticancer evaluation, preliminary mechanism study of novel 1, 2, 3-triazole-piperlongumine derivatives

Synthesis Of Diaryl Ether Substituted Piperazine Derivatives And Their Cytotoxic Activities

Novel Dihydroisoxazoline-Alkyl Carbon Chain Hybrid Artemisinin Analogues (artemalogs): Synthesis and Antitumor Activities

Synthesis and biological evaluation of novel Jiyuan Oridonin A-1,2,3-triazole-azole derivatives as antiproliferative agents.

Synthesis, Characterization, Cytotoxicity, Cellular Imaging, Molecular Docking, and ADMET Studies of Piperazine-Linked 1,8-Naphthalimide-Arylsulfonyl Derivatives

Design, synthesis and biological evaluation of artemisinin derivatives containing fluorine atoms as anticancer agents.

Synthesis And Biological Evaluation Of Novel Acenaphthene Derivatives As Potential Antitumor Agents

Design, facile synthesis and biological evaluations of novel pyrano[3,2-a]phenazine hybrid molecules as antitumor agents.